Objective-SNRK (sucrose nonfermenting 1-related kinase) is a novel member of the AMPK (adenosine monophosphateactivated protein kinase)-related superfamily that is activated in the process of angiogenesis. Currently, little is known about the function of SNRK in angiogenesis in the physiological and pathological conditions. Approach and Results-In this study, in Snrk global heterozygous knockout mice, retina angiogenesis and neovessel formation after hindlimb ischemia were suppressed. Consistently, mice with endothelial cell (EC)-specific Snrk deletion exhibited impaired retina angiogenesis, and delayed perfusion recovery and exacerbated muscle apoptosis in ischemic hindlimbs, compared with those of littermate wide-type mice. Endothelial SNRK expression was increased in the extremity vessel samples from nonischemic human. In ECs cultured in hypoxic conditions, HIF1α (hypoxia inducible factor 1α) bound to the SNRK promoter to upregulate SNRK expression. In the nuclei of hypoxic ECs, SNRK complexed with SP1 (specificity protein 1), and together, they bound to an SP1-binding motif in the ITGB1 (β1 integrin) promoter, resulting in enhanced ITGB1 expression and promoted EC migration. Furthermore, SNRK or SP1 deficiency in ECs ameliorated hypoxia-induced ITGB1 expression and, consequently, inhibited EC migration and angiogenesis. Conclusions-Taken together, our data have revealed that SNRK/SP1-ITGB1 signaling axis promotes angiogenesis in vivo.
A ngiogenesis plays crucial roles in some physiological conditions, including organogenesis and advanced embryonic development, and is also a key process in pathological conditions such as stroke, myocardial infarction, and other ischemic diseases. The major function of the circulatory system is to deliver oxygen and nutrients to all cells and remove waste products within the body. 1, 2 An insufficient blood supply, if not corrected in time, leads to depletion of oxygen and nutrients to vital organs, resulting in organ failure and death. 1, 3, 4 In response to sublethal changes in blood or oxygen supply, mammals have developed several mechanisms during evolution to alleviate ischemic or hypoxic injury. One of these adaptive mechanisms is angiogenesis, a process in which new capillaries form from existing microvessels to restore tissue blood perfusion to ischemic tissues. 5, 6 Overwhelming evidence indicate that one of the most potent stimulators of ischemic angiogenesis is hypoxia or reduced oxygen. 7 Hypoxia promotes the release of multiple classic proangiogenic factors, including fibroblast growth factor, VEGF (vascular endothelial growth factor), and angiopoietin, and this response is reported to be essential for increases in microvascular density. [8] [9] [10] [11] [12] Although HIFs (hypoxia inducible factors) are key regulators of these adaptive hypoxic responses, precisely how these HIF transcription factors promote compensative angiogenesis is not well known. Moreover, the targets of HIF transcription factors in endothelial cells (ECs) remain to be identified. Snf1 (sucrose nonfermenting 1)-related kinase (SNRK) is a serine/threonine kinase and a novel member of the AMPK (adenosine monophosphate-activated protein kinase)-related superfamily. 13, 14 The catalytic domain of SNRK has significant homology with those of AMPK and AMPK-related kinase. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Similar to AMPK, SNRK can be phosphorylated by LKB1 (liver kinase B1) at the Thr 173 residue located in the T-loop domain, 15 and is activated by 5-aminoimidazole-4-carboxamide ribonucleotide and cellular stressors such as glucose deprivation, rotenone, and sorbitol. 25, 26 Recent evidence suggests that SNRK regulates critical cellular processes, including glucose transportation and cell motility.
UCP3 (uncoupling protein 3) pathway. 28 What is more, SNRK is aberrantly expressed in human diseases such as cancer and obesity. 26, 29 The essential role of SNRK in development is best demonstrated by the fact that homozygous deletion of Snrk in mice is embryonically lethal. 30 Although SNRK has been shown to regulate angioblast development in zebrafish, 27, 31 it is not known whether SNRK participates in hypoxia-induced angiogenesis.
The aim of the present study was to elucidate the roles of SNRK in angiogenesis. Here, we report that SNRK protein levels were increased in aorta samples from hindlimb ischemia and nonischemia human. Increase in SNRK expression is observed due to up regulation and binding of HIF1α to SNRK promoter. Furthermore, we found that hypoxia-upregulated SNRK promoted endothelial angiogenesis by activating ITGB1 (β1 integrin)-mediated EC migration. Our results reveal a novel role for SNRK in angiogenesis, and suggest that SNRK upregulation is a valid therapeutic target in preventing and treating ischemic diseases.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Figure 1A through 1C) . To explore the role of SNRK in angiogenesis, we first studied that retinal angiogenesis occurs during the early postnatal days. Snrk heterozygous mice displayed a significantly delay in retinal angiogenesis, reflected from the reduction of vascular diameter and vascularized area ( Figure 1D and 1E ).
Results

Retina Angiogenesis Is Delayed in
Angiogenesis Is Suppressed in Snrk Heterozygous Mouse Model of Hindlimb Ischemia
To further confirm the role of SNRK in angiogenesis, hindlimb ischemia model was used. The left-leg femoral arteries of 2-month-old Snrk f/wt /Cre CMV−/− (WT) mice and Snrk f/wt /Cre CMV+/− (Snrk heterozygous) mice were ligated, and then, blood flow restoration was monitored at different time points. At 2 weeks after surgery, the blood flow ratio returned to 0.33±0.09 in WT mice, whereas the blood flow ratio only recovered to 0.17±0.05 in Snrk heterozygous mice, indicating an obvious impairment in perfusion recovery in Snrk heterozygous mice ( Figure 1F and 1G) .
We also evaluated angiogenesis by immunostaining von Willebrand factor (vWF)-positive cells in ischemic tissues. At 2 weeks after ischemia induction, there was a significant reduction in the number of vWF-positive capillaries surrounding the skeletal muscle fibers in Snrk heterozygous mice compared with Snrk f/wt /Cre CMV−/− (WT) mice ( Figure 1H and 1I).
Hindlimb Ischemia Increases SNRK Expression in the Vasculature of Skeletal Muscle
To further confirm the effects of hypoxia on SNRK, we examined SNRK expression in WT mice subjected to femoral artery ligation. Four weeks after ligation, SNRK expression was significantly increased at the protein (P<0.05) and mRNA (P<0.05) level in the gastrocnemius muscle of the ischemic limbs compared with those in the sham-treated, nonischemic limbs ( Figure IA through IC in the online-only Data Supplement). Moreover, there appeared to be more SNRKpositive cells in ischemic tissues than in the nonischemic counterparts ( Figure ID in the online-only Data Supplement).
Coimmunostaining of SNRK and the EC marker vWF showed that SNRK staining was mainly in the vWF-positive cells ( Figure 1D ). In our mouse model of hindlimb ischemia, SNRK levels were upregulated in the vasculature of skeletal muscles in response to ischemia. In aorta tissues from human, SNRK expression was mainly in ECs ( Figure IE in the online-only Data Supplement). Interestingly, SNRK expression was obviously increased and the increase was mainly in ECs ( Figure IE in the online-only Data Supplement). Thus, both in clinic and our mouse model of hindlimb ischemia, SNRK levels were upregulated in the vasculature of skeletal muscles in response to hypoxia.
Retina Angiogenesis Is Delayed in ECSpecific Deletion Snrk Mice
To target SNRK expression in ECs, EC-specific deletion of Snrk (Snrk 
Endothelial Snrk Deletion Impairs Perfusion Recovery and Angiogenesis in Ischemic Hindlimbs
To determine whether Snrk deficiency impairs ischemiainduced angiogenesis in vivo, the left-leg femoral arteries (WT) mice were ligated, and then, blood flow restoration was monitored at different time points. Before surgery, the ratio of the left-to-right leg blood flow was 1. Directly after surgery, the blood flow ratio dropped by 90% in both mouse groups ( Figure 2C ). At 4 weeks after surgery, the blood flow ratio returned to 0.8 in control mice, whereas the blood flow ratio only recovered to 0.35 in Snrk f/f /Cre VE-Cadh+/− mice, demonstrating a marked impairment in perfusion recovery in Snrk f/f /Cre VE-Cadh+/− mice ( Figure 2C ). We also performed similar hindlimb ischemia studies on 6-month-old male Snrk-Tie2 (TEK receptor tyrosine kinase) Cre endothelial conditional knockout mice (Snrk f/f /Cre tie2+/− ), and observed similar results in that blood flow ratio never recovered in the mutant mice compared with WT mice (Snrk f/WT /Cre tie2−/− or Snrk f/f /Cre tie2−/− ; Figure IIA and IIB in the online-only Data Supplement), and the baselines between the control and mutant mice were already different, and persisted until 21 days. These results suggests that SNRK's effect in mediating angiogenesis is EC autonomous.
We also evaluated angiogenesis by immunostaining vWFpositive cells in ischemic tissues. At 4 weeks after ischemia /Cre VE-Cadh+/− mice, t test analysis at the each time point). E, Immunofluorescent costaining of von Willebrand factor (vWF) and α-actin in the gastrocnemius muscle from mice 4 wk after femoral artery ligation or sham surgery. F, The immunofluorescent staining of vWF in the gastrocnemius muscle was quantitatively analyzed. G, Endothelium-specific deletion of SNRK (sucrose nonfermenting 1-related kinase) exacerbates ischemia-induced muscle apoptosis. Western blot analyses of apoptotic markers, including cleaved PARP (cPARP), cleaved Caspase-3 (cCASP-3), and BCL-2, in skeleton muscle tissues from Snrk Consistent with these data, hindlimb ischemia increased skeleton muscle cell apoptosis in Snrk f/f /Cre VE-Cadh+/− mice compared with that in WT mice, as assessed by the increase in cleaved PARP (poly ADP-ribose polymerase) and caspase-3 levels ( Figure 2G ). Thus, endothelial Snrk deletion inhibits angiogenesis in ischemic skeletal muscle.
HIF1α Mediates HypoxiaInduced SNRK Expression
Hypoxia is often thought of as being a pathological phenomenon, such as in ischemic tissues, whereas the mammalian embryo in fact develops in a low-oxygen environment. 32 Therefore, we next investigated whether and how hypoxia regulates SNRK expression in human umbilical vein ECs (HUVECs). Hypoxia-induced increases in SNRK protein ( Figure 3A and 3B) and mRNA ( Figure 3C ) levels in a timedependent manner and concomitantly upregulated HIF1α expression. 33 Similarly, treatment of HUVECs with cobalt chloride (CoCl 2 ) increased the expression of SNRK and HIF1α ( Figure 3D through 3F).
To establish whether HIF1α is essential for SNRK upregulation, we performed siRNA-mediated knockdown of HIF1α and assessed the effects on SNRK levels in hypoxic conditions. Transfection of HIF1α siRNA, but not control siRNA, in HUVECs ablated the hypoxia-induced increases in SNRK protein and mRNA levels ( Figure 3G through 3I) . Conversely, overexpression of HIF1α in HUVECs markedly increased SNRK protein and mRNA levels in normoxic conditions ( Figure 2J and 2K) . Interestingly, HIF2α knockdown in HUVECs did not alter SNRK protein and mRNA levels in hypoxic or normoxic conditions ( Figure IIIA through IIIC in the online-only Data Supplement), suggesting that hypoxiainduced SNRK expression is HIF1α dependent.
Identification of the HIF1α-Specific Binding Site in the SNRK Promoter
To further define how HIF1α regulates SNRK, the consensus HIF1α-binding site sequence 5'-(A/G)CGTG-3' was used to identify putative binding sites in the human SNRK gene. As expected, 4 putative binding sites were found in the human SNRK promoter, which are located at −843 bp, −592 bp, −584 bp, and −290 bp upstream of the transcription start site ( Figure 3L ). To determine which of these HIF1α-binding sites in the SNRK promoter are functional, we constructed a series of luciferase reporter plasmids containing different lengths of the SNRK promoter, including pGL3 (control), pGL-SNRK-200 (no putative binding sites), pGL-SNRK-400 (1 putative binding site at −290 bp), pGL-SNRK-700 (3 putative biding sites at −290, −584, and −592 bp), and pGL-SNRK-900 (all 4 putative binding sites; Figure 3L ). Next, luciferase activity assays were performed in the plasmid-transfected HUVECs, with or without hypoxia, for 8 hours. All 3 plasmids containing the SNRK promoter regions with the putative HIF1α-binding sites (pGL-SNRK-400, pGL-SNRK-700, and pGL-SNRK-900) showed significantly higher luciferase activities than that of the plasmid containing the SNRK promoter region lacking the putative HIF1α-binding sites (pGL-SNRK-200) and that of the pGL3 control plasmid ( Figure 3M ). Taken together, these results indicate that the putative binding site at −290 bp in the SNRK promoter is the HIF1α-specific binding site.
To further validate this result, we deleted the putative binding site at −290 bp in the pGL-SNRK-700 and pGL-SNRK-900 plasmids. The luciferase activities of pGL-SNRK-900-Δ and pGL-SNRK-700-Δ were sharply decreased by 60±5.7% and 41±4.6% compared with those of pGL-SNRK-900 and pGL-SNRK-700, respectively ( Figure 3M ), demonstrating that the −290 bp HIF1α-binding site was critical for SNRK promoter activity. Moreover, this HIF1α-specific binding site in the SNRK promoter is conserved in 5 mammalian species, including human, chimp, rhesus, mouse, and rat ( Figure 3N ), further indicating its functional relevance.
We further tested whether hypoxia promotes HIF1α binding to the −290 bp site in HUVECs. Chromatin immunoprecipitation assays showed that HIF1α did not bind to the SNRK promoter under normoxic conditions; however, hypoxia dramatically increased HIF1α binding to the SNRK promoter, and this binding was inhibited by siRNA-mediated silencing of HIF1α ( Figure 3O ). Collectively, these results indicate that HIF1α is required for hypoxia-activated SNRK expression in ECs.
SNRK Deficiency Impairs Hypoxia-Induced Lung Vascular EC Migration
Because previous data suggested that SNRK deficiency suppresses angiogenesis in vivo, we next assessed how SNRK regulates angiogenesis in isolated lung EC cultures. VE-Cadh+/− mice migrated across the membrane in transwell migration assays than ECs from control littermates ( Figure 4D and 4E) .
To assess the effects of SNRK on endothelial migration ex vivo, we assessed microvessel sprouting from aortic rings isolated from EYFP These results showed that SNRK deficiency impaired angiogenesis mainly resulting from migration. We next investigated several genes involved with migration using real-time PCR assay. There is no significant difference of the mRNA levels of the growth factors between lung ECs from Snrk mice. These results suggested that SNRK could potentially regulate ITGB1 during EC migration process.
SNRK Is Essential for EC Migration
To confirm SNRK induction in a hypoxic environment is essential for EC function, we determined the impact of altering SNRK levels on angiogenesis in HUVECs. In wound healing assays, SNRK knockdown inhibited HUVECs migration into the wounded areas in normoxic and hypoxic conditions ( Figure   IVA and IVB in the online-only Data Supplement), and in transwell assays, SNRK silencing significantly reduced the numbers of migrating ECs ( Figure IVC We further tested whether ITGB1 overexpression rescues the cell migration defects in SNRK-deficient lung vascular ECs. As expected, in wound healing assays, ITGB1 overexpression promoted the migration of WT lung ECs into the wounded areas, and importantly, ITGB1 overexpression normalized the migration of SNRK-deficient lung ECs into the wounded areas ( Figure 5D and 5E ). In addition, in transwell migration assays, ITGB1 overexpression increased the numbers of WT and SNRK-deficient ECs that migrated across the membranes ( Figure 5F and 5G). The phosphorylation of FAK (focal adhesion kinase) and Src, as downregulation gene of ITGB1, was suppressed in SNRK-deficient ECs compared with lung ECs from WT mice ( Figure 5H ). And ITGB1 overexpression can suppress the reduction of FAK and p Src phosphorylation caused by SNRK deficiency ( Figure 5H ).
ITGB1 Upregulation Promotes Migration in Lung ECs
SNRK Promotes HUVECs Migration by ITGB1 Upregulation
To further confirm that ITGB1 is involved in SNRK-induced EC migration, we next examined whether ITGB1 overexpression can rescue the migration defection caused by SNRK knockdown in HUVECs. As expected, hypoxia increased ITGB1 protein and mRNA levels in HUVECs ( Figure VIIA 
ITGB1 Silencing Abolishes the Enhanced Migration of SNRK-Overexpressing HUVECs
To further establish the essential role of ITGB1 in SNRKinduced EC migration, we next tested whether ITGB1 is required for the observed increase in migration of SNRKoverexpressing HUVECs ( Figure 
SNRK Affect EC Adhesion Through ITGB1 Pathway
The focal adhesion protein paxillin is required for the directional migration of ECs. To further elucidate how SNRK regulates EC migration through ITGB1, we examined the effects of SNRK modulation on HUVEC adhesion. SNRK siRNA-treated cells exhibited a dramatic reduction in paxillin staining and focal adhesions, compared with those of scramble siRNA-treated cells, indicating that SNRK depletion reduces HUVEC adhesion ( Figure IXH and IXI in the online-only Data Supplement). In contrast, ITGB1 overexpression increased the number of HUVEC focal adhesions in the siSNRK-and siScramble-treated cells ( Figure XA and XB in the online-only Data Supplement). Taken together, these data suggest that ITGB1 mediates the effects of SNRK on EC migration via cell adhesion regulation.
Hypoxia Increases the Association Between SNRK and SP1
SP1 (specificity protein 1)-binding sites have been identified within the ITGB1 promoter, and they are required for regulating the promoter activity. 35 To determine whether SNRK interacts with SP1 to regulate ITGB1 expression, we examined the subcellular distribution of SNRK and SP1 in HUVECs by immunofluorescence staining. Consistent with previous reports, 36 SP1 was mainly present in the nucleus. Notably, SNRK was also predominantly detected in the nucleus ( Figure 6A ). We hypothesized that SNRK interacts with SP1 to regulate ITGB1 expression; thus, we investigated whether SNRK directly associates with SP1. Immunoprecipitation of SP1 followed by probing for SNRK or vice versa showed that SNRK does physically associate with SP1 ( Figure 6B ; Figure XIA in the online-only Data Supplement). Moreover, the interaction between SP1 and SNRK was further enhanced in hypoxic conditions ( Figure 6C ; Figure XIB in the online-only Data Supplement).
SNRK and SP1 Coordinately Regulate ITGB1 Expression
Thorough analysis of the ITGB1 gene revealed 2 putative SP1-binding motifs in the human ITGB1 promoter, which are located at −4467 bp and −3263 bp upstream of the transcription start site ( Figure XIC in the online-only Data Supplement). Luciferase reporter plasmids containing different lengths of the ITGB1 promoter were generated and transfected into HEK293 cells. SP1 or SNRK overexpression significantly increased the luciferase activities of the pGL-ITGB1-3263 and pGL-ITGB1-4467 plasmids; each plasmid contains the −3263 bp SP1-binding motif ( Figure XID in the online-only Data Supplement). However, these luciferase activities were significantly decreased after deletion of the −3263 bp motif, suggesting that SP1 recognizes and binds to the human ITGB1 promoter at the −3263 bp motif ( Figure  XID in the online-only Data Supplement).
To assess whether an intact SNRK/SP1 complex is crucial for SP1 binding to the ITGB1 promoter, we performed chromatin immunoprecipitation assays in SNRK-overexpression and SNRK-deficient conditions. In HUVECs, SNRK overexpression enhanced SP1 binding to the ITGB1 promoter ( Figure 6D ). In contrast, in lung ECs, SNRK deficiency inhibited SP1 binding to the ITGB1 promoter ( Figure 6E ).
We reasoned that SNRK and SP1 coordinately regulate ITGB1 expression through binding to the ITGB1 promoter at the SP1-binding site. To test this, we measured ITGB1 expression after transfection of HUVECs with SNRK and SP1 , t test analysis). H, Cell lysates were subjected to Western blot analysis to detect the levels of SNRK, ITGB1, p-FAK, p-SRC, and β-actin.
plasmids. Transfection of the SNRK or SP1 plasmid alone slightly increased ITGB1 protein and mRNA levels, whereas transfection of the SNRK and SP1 plasmids together dramatically increased ITGB1 protein and mRNA levels ( Figure   XIIA through XIIC in the online-only Data Supplement). In addition, SP1 silencing abrogated the increased ITGB1 expression (protein and mRNA) in SNRK-overexpressing HUVECs ( Figure 6F through 6H) . Similarly, SNRK knockdown /Cre VE-Cadh+/− mice (E). The chromatin was immunoprecipitated with a SP1 antibody. Rabbit IgG was used as a negative control. A 210 bp product containing the SP1-binding site was amplified by PCR from immunoprecipitated DNA or 10% of the chromatin input. F through H, HUVECs were transfected with SP1 siRNA and SNRK-HA plasmid for 48 h. F, Cell lysates were subjected to Western blot analysis to detect the levels of SP1, SNRK, ITGB1 (β1 integrin), and β-actin. G, ITGB1 levels were quantified by densitometric analysis of the Western blots (n=6, *P<0.05 vs control; #P<0.05 vs scramble siRNA, t test analysis). H, ITGB1 expression was measured by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR; n=6, *P<0.05 vs control; #P<0.05 vs scramble siRNA, t test analysis). I through K, HUVECs were transfected with SNRK siRNA and SP1-HA plasmid for 48 h. I, Cell lysates were subjected to Western blot analysis to detect the levels of SP1, SNRK, ITGB1, and β-actin. J, ITGB1 levels were quantified by densitometric analysis of the Western blots (n=6, *P<0.05 vs control; #P<0.05 vs scramble siRNA, t test analysis). K, ITGB1 expression was measured by qRT-PCR (n=6, *P<0.05 vs control; #P<0.05 vs scramble siRNA, t test analysis). L and M, HUVECs were cotransfected with SP1, SNRK, and scramble siRNAs, in various combinations, for 48 h in normoxic or hypoxic conditions. L, The levels of HIF1α, SP1, SNRK, ITGB1, and β-actin were measured by Western blotting. M, ITGB1 levels were quantified by densitometric analysis of the Western blots (n=3, *P<0.05 vs normoxia, t test analysis).
abolished the increased ITGB1 expression (protein and mRNA) in SP1-overexpressing HUVECs ( Figure 6I through 6K). Finally, under hypoxic conditions, knockdown of SNRK and SP1, individually and in combination, prevented hypoxia-enhanced ITGB1 expression ( Figure 6L and 6M) . These results support the notion that SNRK and SP1 form a complex that binds the ITGB1 promoter and synergistically upregulates ITGB1 expression.
Discussion
In this study, we have discovered that in ECs, HIF1α-induced SNRK upregulated ITGB1 expression, promoted EC migration, and increased the formation of endothelial tube-like structures. Conversely, SNRK silencing impaired EC migration and tube formation. Moreover, endothelial Snrk deletion impaired new vessel formation both in physiological and pathological conditions and exacerbated ischemic injury in hindlimb ischemia mouse model. Our results suggest that the SNRK/SP1-ITGB1 signaling axis is essential for angiogenesis in vivo.
There are several novel findings of this study. First, we uncovered SNRK is involved with angiogenesis both in physiological and pathological conditions. In the healthy condition, sprouting angiogenesis, one vital step in the development of the retinal vasculature, is characterized by sprouts with ECs. And in ischemic diseases, sprouting of capillaries leads to an increase of their density, resulting from the depletion of oxygen and nutrients. It is considered that angiogenesis is initiated after tissue ischemia. In normal physiological conditions, retinal angiogenesis is suppressed both in SNRK global heterozygous knockout mice (Snrk f/wt /Cre CMV+/− ) and EC-specific Snrk knockout (Snrk f/f /Cre VE-Cadh+/− ) mice. In pathological condition, endothelial SNRK expression was increased in aorta tissues from patients with extreme vascular disease, while ischemia induced SNRK expression in ECs in hindlimb ischemic mouse model. Consistent with this finding, SNRK is mainly expressed in fetal CD34 + hematopoietic progenitor cells. 27 Additionally, blood perfusion and endogenous angiogenesis were suppressed after femoral ligation in SNRK global heterozygous knockout mice. We also observed decreased angiogenesis in the ischemic skeletal muscles of endothelial Snrk-deleted mice. Mice with EC-specific Snrk knockout exhibited impaired angiogenesis and delayed perfusion recovery in ischemic hindlimbs when compared with those of their littermate controls. It is recently reported that cardiomyocyte-specific SNRK knockout mice also show cardiac metabolism and functional deficits, 30 and SNRK can decrease mitochondrial uncoupling, resulting in the cardiac protection against ischemia/reperfusion injury. 28 Overall, our results suggest that SNRK plays an essential role of angiogenesis, and that ischemic induction of endothelial SNRK is a key compensative adaptation to alleviate ischemic injury.
Second, we established a novel pathway in which hypoxiaactivated a HIF1α-SNRK/SP1-ITGB1 axis in ECs to promote angiogenesis and alleviate ischemic injury. Several lines of evidence suggest that this axis is essential for ischemic adaptations to reduce tissue injury. First, hypoxia/ischemia-induced HIF1α expression and concomitantly upregulated SNRK mRNA and protein expression. HIF1α knockdown completely abolished hypoxia-induced SNRK expression, whereas HIF1α overexpression increased SNRK expression. Thus, SNRK seems to be a HIF1α target in response to hypoxia. Indeed, the SNRK promoter has a HIF1α regulatory consensus sequence, or hypoxia response element, and we showed that HIF1α bound to the hypoxia response element of the SNRK promoter and increased its transcriptional activity in hypoxic conditions.
A third important finding of the present study is the identification of ITGB1 as the key mediator of SNRK-enhanced EC migration and angiogenesis. We found that SNRK upregulated ITGB1 expression by forming a complex with SP1. This complex bound to the ITGB1 promoter and increased its transcriptional activity. SP1 or SNRK silencing reduced the binding of this complex to the ITGB1 promoter. In luciferase activity assays, SNRK or SP1 overexpression increased, whereas SNRK or SP1 knockdown suppressed, ITGB1 promoter luciferase activity. Further, SNRK and SP1 combined overexpression dramatically increased, whereas SNRK or SP1 silencing reduced, ITGB1 mRNA and protein expression. Importantly, ITGB1 overexpression rescued the inhibitory effects of SNRK knockdown on EC migration 27 and tube formation. Conversely, ITGB1 knockdown abrogated the enhanced migration and tube formation of SNRK-overexpressing ECs. Together, these data suggest that SNRK promotes angiogenesis by activating ITGB1-mediated EC migration and adhesion. Interestingly, ITGB1 overexpression in endothelial precursor cells has been directly implicated in augmenting angiogenesis in ischemic legs. 37 Our data that SNRK is a key regulator of ischemic angiogenesis combined with ITGB1's role in promoting angiogenesis in ischemic conditions, and hypoxia-induced SNRK triggers induction of ITGB1 expression in ECs provide a direct mechanistic link between the 2 proteins in promoting ischemia-related angiogenesis vivo.
In conclusion, we showed that hypoxia-induced SNRK expression via HIF1α upregulation. The increased SNRK interacted with SP1 to enhance ITGB1 expression, which in turn, promoted EC migration and increased new vessel formation. Thus, our data revealed SNRK as a novel molecule promoting hypoxia-induced angiogenesis, indicating that SNRK is a potential therapeutic target to treat ischemic diseases and other diseases associated with angiogenesis.
